Results(4639)
Clinical Practice Research Datalink
Birth registry
Hospital discharge records
Other
Primary care medical records
United Kingdom
First published:
30/04/2026
Data source
Human
Record completeness: 94%
Risk of 4 obesity-related cancers after GLP-1 receptor agonist use
United States
EU PAS number:
EUPAS1000000990
First published:
30/04/2026
Study
Planned
Utilization and Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia
Canada
EU PAS number:
EUPAS1000000387
First published:
30/04/2026
Study
Finalised
Safety and effectiveness of RZV in adults ≥18 years of age with Systemic lupus erythematosus (SLE) or Multiple sclerosis (MS) (EPI-ZOSTER-041 VS US DB 215104)
United States
EU PAS number:
EUPAS107073
First published:
30/04/2026
Study
Ongoing
A Prospective Real-World Study Evaluating Objective Response Rate and Duration of Response of Tazemetostat Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma Following at Least Two Prior Lines of Treatment
United States
EU PAS number:
EUPAS1000000766
First published:
30/04/2026
Study
Cancelled
Sylvia Lawry Centre for Multiple Sclerosis Research, The Human Motion Institute
Germany
First published:
29/04/2026
Institution
Not-for-profit
ENCePP partner
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Patients and/or Caregivers to Assess Understanding of the Risks with the BKEMV™ Risk Evaluation and Mitigation Strategy (REMS) (20240214)
United States
EU PAS number:
EUPAS1000000368
First published:
29/04/2026
Study
Ongoing
Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
United States
EU PAS number:
EUPAS45952
First published:
29/04/2026
Study
Ongoing
An Active Surveillance, Post-Authorization Study to Assess Tofacitinib Utilization Patterns and to Characterize the Safety of Tofacitinib Use in Patients with Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data from a US Administrative Healthcare Claims Database
United States
EU PAS number:
EUPAS36041
First published:
29/04/2026
Study
Ongoing
COHORT STUDY ON THE SAFETY OF BIMEKIZUMAB IN PATIENTS WITH PLAQUE PSORIASIS, PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR HIDRADENITIS SUPPURATIVA: A NON-INTERVENTIONAL POST AUTHORIZATION STUDY
France
United States
EU PAS number:
EUPAS1000000003
First published:
29/04/2026
Study
Ongoing
A regulatory non-interventional study to monitor the safety and efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean patients with Chronic Kidney Disease (CKD)
Korea, Republic of
EU PAS number:
EUPAS107293
First published:
29/04/2026
Study
Ongoing
CABFIDENCE: Global Real-World Evidence Cohort Study to evaluate Utilization, Clinical and Patient-Reported Outcomes among CAB+RPV LA users (224047)
Australia
France
Italy
Japan
Portugal
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000616
First published:
29/04/2026
Study
Ongoing
Team Gesundheit GKV Claims data
Administrative healthcare records (e.g., claims)
Germany
First published:
29/04/2026
Data source
Human
Record completeness: 83%
Semmelweis University Clinical Data
Emergency care discharge records
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Hungary
First published:
29/04/2026
Data source
Human
Record completeness: 91%
Global Registry For Novel Therapies In Bone & Endocrine Conditions
Disease registry
Argentina
Armenia
Australia
Belgium
Brazil
Bulgaria
China
Czechia
France
Georgia
Germany
Greece
Hong Kong
Italy
Korea, Republic of
Malaysia
Poland
Portugal
Saudi Arabia
Slovenia
Sri Lanka
Sweden
United Kingdom
United States
First published:
29/04/2026
Data source
Human
Record completeness: 93%
TaUH patient cohort (FinOMOP)
Hospital inpatient records
Hospital outpatient visit records
Finland
First published:
29/04/2026
Data source
Human
Record completeness: 97%
BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)
Hospital discharge records
Pharmacy dispensing records
Primary care medical records
Spain
First published:
29/04/2026
Data source
Human
Record completeness: 97%
Comparing Weight Gain on F/TAF and Placebo Using DISCOVER and iPrEx Study Data
Austria
Brazil
Canada
Denmark
Ecuador
France
Germany
Ireland
Italy
Netherlands
Peru
South Africa
Spain
Thailand
United Kingdom
United States
EU PAS number:
EUPAS1000000509
First published:
29/04/2026
Study
Finalised
DARWIN EU® - Azathioprine - user characteristics
Germany
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS1000000322
First published:
29/04/2026
Study
Finalised
European real-Life use of Eludril eXtra among 4 countries (ELEX4)
Bulgaria
Greece
Poland
Portugal
EU PAS number:
EUPAS1000000986
First published:
23/04/2026
Study
Finalised
Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated With Either Blinatumomab or Chemotherapy (20180130) (Paediatric long-term follow up study)
Argentina
Brazil
Bulgaria
Canada
Colombia
Czechia
Finland
Greece
Israel
Italy
Mexico
Poland
Spain
Taiwan
Türkiye
United States
EU PAS number:
EUPAS33862
First published:
23/04/2026
Study
Ongoing
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
European Union
United Kingdom
United States
EU PAS number:
EUPAS1000000891
First published:
23/04/2026
Study
Planned
Evaluating the utilisation of Urospir® (spironolactone) in paediatric and adult patients in the United Kingdom: A drug utilisation study using the Clinical Practice Research Datalink (CPRD) database
United Kingdom
EU PAS number:
EUPAS1000000988
First published:
23/04/2026
Study
Planned
Real-world use of Breztri/Trixeo for the management of COPD in a UK primary care population
United Kingdom
EU PAS number:
EUPAS104156
First published:
23/04/2026
Study
Planned
Long-term cardiovascular safety and real-world use of eptinezumab - An observational, historical cohort study of patients initiating eptinezumab in routine clinical practice
Denmark
Germany
Italy
United States
EU PAS number:
EUPAS1000000882
First published:
22/04/2026
Study
Planned
Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients with Submental Fullness due to Submental Fat: A Postmarketing Surveillance Study in Korea
Korea, Republic of
EU PAS number:
EUPAS23762
First published:
22/04/2026
Study
Finalised
A Post-Marketing Safety Study of Mounjaro® (Tirzepatide) in Chinese Participants who are Overweight or have Obesity with or without Type 2 Diabetes Mellitus in a Real-World Setting
China
EU PAS number:
EUPAS1000000461
First published:
22/04/2026
Study
Ongoing
Fitness-for-Use Assessment across Four Data Sources for Real-World Safety and Effectiveness Studies of CAR-T cell therapies
France
United Kingdom
United States
EU PAS number:
EUPAS1000000955
First published:
22/04/2026
Study
Ongoing
Identification, Characterisation, and Data Quality Assessment of Data Sources for Real-World Safety and Effectiveness Studies of Chimeric antigen receptor T-cell (CAR-T cell) therapies
European Union
Iceland
Norway
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS1000000954
First published:
22/04/2026
Study
Ongoing
Body weight and waist circumference change in midlife women treated with tirzepatide by menopausal status: an observational study in UK primary care
United Kingdom
EU PAS number:
EUPAS1000000983
First published:
22/04/2026
Study
Planned
An OTIS/MotherToBaby Pregnancy Registry-based observational cohort study to evaluate pregnancy and infant outcomes in individuals exposed to Boostrix as of the 1st day of the 27th week of gestation in the US (EPI-PERTUSSIS-075 VS US PR 219588)
United States
EU PAS number:
EUPAS105107
First published:
22/04/2026
Study
Ongoing
Real-life Enfortumab Vedotin Outcomes as First-line Urothelial Carcinoma Treatment in the Non-interventional Observational and Nationwide French Study
France
EU PAS number:
EUPAS1000000763
First published:
22/04/2026
Study
Planned
Enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and immunotherapy: a multicenter, non-interventional study in Italy (EVIDENCE)
Italy
EU PAS number:
EUPAS107848
First published:
22/04/2026
Study
Ongoing
Registo Nacional de Doentes Reumáticos
Disease registry
Portugal
First published:
17/04/2026
Data source
Human
Record completeness: 93%
Valproate: survey on awareness of teratogenicity risk and impact of risk minimisation measures in women of childbearing age.
Belgium
EU PAS number:
EUPAS1000000735
First published:
17/04/2026
Study
Ongoing
Chronic inflammatory immune-mediated diseases and immunosuppressive drugs: What evidence would you like to see generated from real-world data?
Italy
EU PAS number:
EUPAS1000000982
First published:
16/04/2026
Study
Finalised
SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.
Denmark
Finland
France
Italy
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000288
First published:
16/04/2026
Study
Planned
Real-world Persistency, Effectiveness, and Safety Among Patients with NMOSD Treated with Inebilizumab (20250110)
United States
EU PAS number:
EUPAS1000000958
First published:
16/04/2026
Study
Ongoing
Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments
Netherlands
United Kingdom
United States
EU PAS number:
EUPAS12116
First published:
16/04/2026
Study
Finalised
Safety and effectiveness of Pradaxa oral pellet formulation for treatment of acute venous thromboembolic events (VTE) and/or for risk reduction of recurrence of VTE in pediatric patients aged 3 months to less than 12 years in a real world setting: a prospective non-interventional study conducted in the United States
United States
EU PAS number:
EUPAS1000000981
First published:
16/04/2026
Study
Discontinued
Compare data sources